Tysabri Withdrawal Prompts Biogen Idec To Suspend Financial Guidance

Company plans to issue revised guidance in May after warning investors not to rely on previous financial forecasts. Announcement coincides with news that a third diagnosis of PML was discovered in a clinical trial for Tysabri.